Antibody Industry Trends

This morning, Helicore Biopharma emerged from stealth with $65M in Series A funding. They are focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists, with their most advanced asset, HCR-188, being a clinical stage monoclonal antibody (mAb) designed to bind GIP.

Biointron’s Q4 2024 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2024 (October, November, December).

Trispecific antibodies are an advanced class of engineered therapeutic proteins designed to simultaneously bind three distinct targets, offering enhanced precision and versatility in treating complex diseases, particularly cancer and immune-related disorders.

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules designed to degrade specific proteins by recruiting an E3 ubiquitin ligase to the target protein, leading to its ubiquitylation and subsequent degradation by the proteasome. This novel mechanism enables PROTACs to eliminate on

According to Research and Markets, the global market for Fc and glycoengineered antibodies is projected to be worth US$38.8 billion in 2024. Over the next decade, the growth in opportunities for drug developers is expected to be driven by an increasing patient population and rising demand for these

Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected mosquitoes. Of the five species of Plasmodium that cause malaria, Plasmodium falciparum is the deadliest, responsible for the majority of cases and deaths, particularly in Africa, where young children are

This report aims to explore the events and trends of the biopharmaceutical industry in 2024 (YTD December 2024). This year, 22 novel antibody drugs have been approved by at least one regulatory agency around the world.

Alzheimer’s research has undergone transformative changes in recent years, characterized by breakthroughs, controversies, and a reevaluation of long-held theories. Recently, BioArctic announced a global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-

The FDA has revoked Emergency Use Authorizations (EUAs) for multiple COVID-19 monoclonal antibody (mAb) therapies, including those developed by Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron. This decision reflects the challenges of targeting rapidly mutating viruses like SARS-CoV-2, which

Antibody drugs offer targeted and effective therapies for inflammatory conditions such as chronic diseases like rheumatoid arthritis, Crohn's disease, and psoriasis. By specifically binding to pro-inflammatory cytokines or their receptors, monoclonal antibodies help modulate the immune response,

Biparatopic antibodies (bpAbs) are bispecific antibodies which bind distinct, non-overlapping epitopes on an antigen. This unique binding mode allows for superior affinity and specificity, promotes antagonism, locks target conformation, and results in higher-order target clustering. The antibody-target complexes can elicit strong agonism, increase immune effector function, or result in rapid target downregulation and lysosomal trafficking.

As antibody-drug development accelerates, ensuring consistent binding affinity, stability, and specificity is critical to improving treatment outcomes. Recent advances in antibody sequencing, artificial intelligence, and high-throughput screening have bolstered efforts to produce reliable antibody candidates more efficiently.